Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):997-1006. doi: 10.1016/s0360-3016(00)00769-0.

Abstract

Purpose: To compare the effects of concurrent administration of cisplatinum (40 mg/m(2)/weekly) with radiation therapy (C-RT) to those induced by radiation therapy alone (RT) on the immune function of patients with locally advanced cervical cancer.

Methods and materials: In 8 prospectively randomized patients (i.e., 4 receiving RT vs. 4 receiving C-RT), lymphocyte populations including CD3+, CD4+ and CD8+ T-cell subsets, B cells (CD19+) and natural killer cells (CD56+, CD16+, CD3-) were studied before, during, and after therapy. Expression of the activation marker CD25 on CD3+ T cells, intracellular levels of perforin in CD8+ and CD56+ cells, and interferon-gamma (IFN-gamma) and IL-2 in CD4+ and CD8+ T cells was also measured. Finally, lymphoblast transformation and natural killer (NK) cytotoxic activity were assessed.

Results: Both RT and C-RT significantly decreased the mean absolute number of all lymphocyte subsets compared to pretreatment levels (p > 0.001). However, no differences were detected in the characteristics or the magnitude of the lymphopenia induced by the two treatments. Both RT and C-RT increased similarly the percentages of CD25-positive lymphocytes (p > 0.001), and significantly decreased PHA-induced T-cell lymphoblast transformation (p > 0.001) and NK cytotoxic activity against K562 cells (p > 0.001). The percentage of perforin-positive and CD8+ T cells was not altered during either treatment, whereas the percentage of perforin-positive and CD56+ cells was significantly reduced during both treatments, and correlated with reduced cytotoxicity against K562 cells. The percentages of CD8+ IFN-gamma+ and CD4+ IFN-gamma+ T cells as well as that of CD8+ IL-2+ and CD4+ IL2+ T cells were not significantly altered by C-RT compared to RT alone. Finally, with both regimens, NK cells and B-cell numbers showed a more rapid recovery than T-cell numbers.

Conclusion: Administration of concurrent cisplatinum to radiation may synergistically increase cytotoxic effects of radiation on tumor cells but does not alter the magnitude and the characteristics of radiation-induced immunosuppression.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use*
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / radiation effects
  • Interferon-gamma / metabolism
  • Interleukin-2 / metabolism
  • Killer Cells, Natural
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / radiation effects
  • Lymphocyte Subsets / drug effects*
  • Lymphocyte Subsets / radiation effects*
  • Membrane Glycoproteins / metabolism
  • Middle Aged
  • Perforin
  • Pore Forming Cytotoxic Proteins
  • Prospective Studies
  • Receptors, Interleukin-2 / metabolism
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / radiotherapy*

Substances

  • Antineoplastic Agents
  • Interleukin-2
  • Membrane Glycoproteins
  • Pore Forming Cytotoxic Proteins
  • Receptors, Interleukin-2
  • Perforin
  • Interferon-gamma
  • Cisplatin